Purchase this article with an account.
M. J. Tolentino, N. Mehta, P. Harrell, M. J. Espiritu; Monitoring Anti-VEGF Therapy for Exudative Age-Related Macular Degeneration With the Preferential Hyperacuity Perimeter. Invest. Ophthalmol. Vis. Sci. 2009;50(13):246.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To describe changes seen on Preferential Hyperacuity Perimeter in exudative age-related macular degeneration (AMD) between baseline and 1 week after being treated with anti-VEGF therapy
Nine patients (10 eyes) with subfoveolar choroidal neovascularization (CNV) confirmed by fluorescein angiography and optical coherence tomography (OCT) were assessed with spectral domain OCT and macular visual field using the PHP (area and intensity of distortion). These tests were done prior to and 1 week after injections.
Bevacizumab was injected in 5/10 eyes, ranibizumab in 3/10 eyes and pegaptanib in 2/10 eyes. Improvement in PHP distortion intensity and area was seen in 7/10 eyes. Discernible OCT changes was only seen in 4/10 eyes. Visual acuity improvement was seen in only 2/10 eyes remained the same in 8/10 eyes.
PHP appears to be able to detect subtle functional changes after 1 week post anti-VEGF treatment for exudative age related macular degeneration.
This PDF is available to Subscribers Only